The American Academy of Dental Sleep Medicine (AADSM) announced that 2,500 dentists across the country have achieved AADSM Qualified Dentist status, strengthening patient access to oral appliance therapy (OAT) for obstructive sleep apnea (OSA). OAT offers a comfortable, clinically-proven treatment option for snoring and OSA. The therapy uses a custom-fit oral […]
Tag: OBSTRUCTIVE SLEEP APNEA (OSA)
Eight Things to Consider Before Choosing a Home Sleep Testing Device
Home sleep testing has come a long way over the past decade. The industry has moved beyond simply asking whether a patient can be tested at home. Today, the conversation centers around how effectively, accurately, comfortably, and efficiently that testing can be performed. After more than 16 years in the […]
Haynes Boone Advises Cathay Capital and ReDream Brands on Strategic Sleep Health Transactions
Haynes Boone represented Cathay Capital and its portfolio company, cpap.com, in the acquisitions of Lofta, LLC from a subsidiary of Accendra Health, Inc, and The CPAPShop from a subsidiary of AdaptHealth Corp. with which a joint venture relationship was also structured, a debt refinancing with Twin Brook Capital Partners, and […]
CPAP Provider Competency Program Sets the Bar
The ASA has launched a brand new service to the CPAP industry – the CPAP Provider Competency Program. It offers CPAP providers an independent industry-wide education program for CPAP professionals who initiate and maintain patients on CPAP therapy. “This program is a way for CPAP providers to demonstrate their commitment […]
ReDream Brands Launches as the Leading Direct-to-Consumer Platform for Sleep Apnea and Sleep Health
Cathay Capital announced the launch of ReDream Brands, a new consumer sleep health platform dedicated to helping millions of people achieve better sleep and healthier lives. The platform brings together four of the industry’s most recognized direct-to-consumer brands: cpap.com, The CPAP Shop, Lofta and sleeping.com, creating a leading platform for […]
TAP Sleep Care Combination Therapy Delivers 95% AHI Reduction in Severe CPAP-Resistant OSA
TAP Sleep Care highlighted clinical evidence on Combination Therapy for CPAP-Resistant Obstructive Sleep Apnea from Martin A. Denbar, DDS, DABDSM, Diplomate of the American Board of Dental Sleep Medicine and Adjunct Assistant Professor in the Department of Internal Medicine at Texas A&M School of Medicine (Texas Dental Sleep Services). The […]
AI Identifies Previously Unrecognized Health Insights in Routine Sleep Studies
A novel AI model can use information collected during routine sleep studies to identify patients’ long-term health risks, according to a new study published in Nature Communications. Developed by a multidisciplinary research team, the model uncovered hidden sleep patterns linked to risks including heart disease, cognitive decline and death. The […]
HoneyNaps Wins FDA Clearance for AI Sleep Analysis Device
HoneyNaps, an AI-based sleep medicine company, announced that SOMNUM V3.0, its AI diagnosis software for polysomnography (PSG) analysis, has received U.S. Food and Drug Administration (FDA) clearance under clearance number K253390. SOMNUM is clinical decision support software designed to assist medical professionals in analyzing PSG data, including sleep staging and […]
Ognomy Sleep Raises $20M Series A to Expand AI-Enabled Sleep Apnea Care
Ognomy Sleep, announced the closing of a $20 million Series A financing round led by Catalyst Investors, with participation from Blue Heron Capital. The round also included new and follow-on investments from Impellent Ventures, LaunchNY, Excell and Upstate Biotech Ventures, University of Buffalo, and strategic partners who have supported the company’s […]
LivaNova Shares Positive 12-Month Results From Obstructive Sleep Apnea Study
Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]













